And we've been able to really increase the number of partners leveraging OmniChicken by about 10x, since the time it was acquired, and became part of the OmniAb platform technology.

Source: https://seekingalpha.com/article/4591785-omniab-inc-oabi-q4-2022-earnings-call-transcript?source=feed_all_articles

My review will reflect Ligand's financial results on a continuing operations basis, now that OmniAb -- now that the OmniAb spin out is complete.

Source: https://seekingalpha.com/article/4580941-ligand-pharmaceuticals-inc-lgnd-q4-2022-earnings-call-transcript?source=feed_all_articles

My review will reflect Ligand's financial results on a continuing operations basis, now that OmniAb -- now that the OmniAb spin out is complete.

Source: https://seekingalpha.com/article/4580941-ligand-pharmaceuticals-inc-lgnd-q4-2022-earnings-call-transcript?source=feed_all_articles

OmniAb has a beta of -0.54, meaning that its stock price is 154% less volatile than the S&P 500. Comparatively, OmniAb’s peers have a beta of 5.59, meaning that their average stock price is 459% more volatile than the S&P 500.

Source: https://www.dailypolitical.com/2023/08/12/reviewing-omniab-oabi-and-the-competition.html

OmniAb is a biotech with a strongly positive differentiator in its business model.

Source: https://seekingalpha.com/article/4657340-omniab-fabulous-business-as-a-base-for-speculative-biotech-investors?source=feed_all_articles

Turning now to our financial results, as a reminder OmniAb was part of Ligand for the first 10 months of the year.

Source: https://seekingalpha.com/article/4591785-omniab-inc-oabi-q4-2022-earnings-call-transcript?source=feed_all_articles